AQ-13 dihydrochloride

AQ-13 dihydrochloride is an aminoquinoline antimalarial drug that is effective against chloroquine-resistant strains of Plasmodium falciparum.

Signaling Pathways >> Others >> Others

Research Areas >> Infection

Slight decreases in the PCE/RBC ratio are observed in male and female rats treated with CQ and in females only treated with AQ-13; however, none of these changes is statistically significant[1].

Rats[1] Male and female Sprague-Dawley rats are used and are 8-9 weeks of age at the time of dose administration. Micronucleus evaluations are conducted in conjunction with repeatdose toxicity studies. Rats are orally administered AQ-13 or CQ in water. Rats are given a “loading dose” followed by maintenance doses of one-half the loading dose administered 12 hr later and daily thereafter for 6 additional days[1].

[1]. Riccio ES, et al. Genetic toxicology testing of the antimalarial drugs chloroquine and a new analog, AQ-13. Environ Mol Mutagen. 2001;38(1):69-79.

Captisol | Cyclosporin A | H2DCFDA | 0MPTP hydrochloride | GW4869 | Etomoxir | TD139 | Mitoquinone mesylate | GSK2795039 | JC-1 | BAPTA-AM | AP 20187 | Setanaxib (GKT137831) | D-Luciferin | Crotaline